Skip navigation

Empower

Hereditary cancer testing, made accessible

Empower is a genetic test for those who want to know more about their risk of developing cancer, why it might be common in their family, or want to inform treatment options following a cancer diagnosis.

Empower screens for genes associated with increased risk for common hereditary cancers. Our Empower multi-cancer panels include commonly screened-for genes associated with 12+ types of cancer.

The Empower Hereditary Cancer Test is Designed with Your Practice in Mind

Five panel options with up to 81 genes across 12+ common hereditary cancer types, and customizable gene panels with 190+ gene options. Genes can be selected individually or added by selecting a particular organ system of interest.

Hereditary breast and ovarian cancer syndrome

Genes: BRCA1, BRCA2

Lynch syndrome

Genes: MLH1, MSH2, MSH6, PMS2, EPCAM

Breast, ovarian, endometrial cancers and Lynch syndrome genes

Commonly screened-for hereditary cancer genes, plus genes with emerging evidence of elevated cancer risks

Genes: ATM, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, NBN, NF1, PALB2, PMS2, PTEN, RAD51C, RAD51D, STK11, TP53

Most commonly screened-for hereditary cancer genes across eight cancer types

Genes: APC, ATM, AXIN2, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, EPCAM, GALNT12, GREM1, HOXB13, MEN1, MITF, MLH1, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NTHL1, PALB2, PMS2, POLD1, POLE, PTEN, RAD51C, RAD51D, RNF43, RPS20, SMAD4, STK11, TP53, VHL

Commonly screened-for hereditary cancer genes, plus genes with emerging evidence of elevated cancer risks

Genes: AIP, ALK, APC, ATM, AXIN2, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDC73, CDH1, CDK4, CDKN1B, CDKN1C, CDKN2A, CEBPA, CHEK2, CYLD, DDX41, DICER1, EGFR, EPCAM, EXT1, EXT2, FH, FLCN, GATA2, GREM1, HOXB13, KIT, LZTR1, MAX, MEN1, MET, MITF, MLH1, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NF2, NTHL1, PALB2, PDGFRA, PHOX2B, PMS2, POLD1, POLE, POT1, PRKAR1A, PTCH1, PTEN, RAD51C, RAD51D, RB1, RET, RHBDF2, RUNX1, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, SMARCB1, SMARCE1, STK11, SUFU, TERC, TERT, TMEM127, TP53, TSC1, TSC2, VHL, WT1

*Breast STAT panel available with 10 breast cancer genes reported within 5-7 calendar days + 30 additional genes reported within 2 weeks. Breast STAT genes include ATM, BARD1, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PTEN, STK11 and TP53.

View and create your own test panel

  • Choose from over 190 genes associated with 12+ organ systems
  • Add or remove single genes to build test panels with a single click
  • Customize and save panels to use in the future
alt text

RNA Analysis for Empower

RNA analysis for Empower provides even more health insights, with no additional sample required. RNA testing can help to improve detection and classification of certain variants that fall within splice site regions.

If there is evidence that a variant detected may impact splicing, RNA analysis is completed. An updated report is automatically issued to you and your patient if a variant is reclassified with RNA analysis.

Testing includes VUS splice sites across 54 high and moderate penetrance genes.

alt text

Patient management recommendations based on medical guidelines

Actionable reports to guide next steps, including:

  • Detect cancer at its earliest, most treatable stage
  • Identify risk-reducing medications and surgeries
  • Inform surgical and therapeutic decisions following a cancer diagnosis
  • Notify family members to help them proactively manage hereditary cancer risk

Tyrer-Cuzick results for a comprehensive breast cancer risk assessment

  • Patients without a breast cancer-related gene mutation may still have increased risk for breast cancer based on their family cancer history and estrogen exposure over their lifetime.
  • Patients with ≥20% remaining lifetime breast cancer risk qualify for insurance coverage for preventive screenings including annual breast MRI surveillance in addition to an annual mammogram.
  • Tyrer-Cuzick evaluations are recommended by medical guidelines to calculate a woman’s breast cancer risk in the next 5 years and over the course of her lifetime.
  • Empower reports offer clear medical management information based on genetic and family history risk.

Natera is committed to patient affordability

Natera is proud to be an in-network provider with most health plans, including Anthem, Cigna, and UnitedHealthcare.

 

For patients without adequate insurance coverage, Natera also offers self-pay pricing and compassionate care options.

EMP-clin-high-risk

Disclaimers : Bellcross CA, Peipins LA, McCarty FA, Rodriguez JL, et al. Genet Med. Characteristics associated with genetic counseling referral and BRCA1/2 testing among women in a large integrated health system. 2015 Jan;17(1):43–50. Patel SG, Ahnen DJ, Kinney AY, et al. Am J Gastroenterol. Knowledge and uptake of genetic counseling and colonoscopic screening among individuals at increased risk for lynch syndrome and their endoscopists from the family health promotion project. 2016 Feb;111(2):285-93.

Many patients at high risk for hereditary cancer are not tested

When to consider hereditary cancer testing

EMP_Clin_1-50 years or younger

Personal or family history of cancer at age 50 or younger

EMP_Clin_2-different cancer

Personal or family history of ovarian, male breast or pancreatic cancer

EMP_Clin_3-multiple

Multiple cancers or tumors on the same side of the family

EMP_Clin_4-Ashkenazi ancestry

Ashkenazi ancestry

EMP_Clin_5-Cancer patient

Your patient is concerned about other familial cancer patterns

Is Empower right for you?

We’re here to help you find out



References

1Cancer risk estimates for a positive result are typically based on individuals with a family or personal history of cancer. NCCN Clinical Practice Guidelines in Oncology Genetic/Familial High Risk Assessment: Breast, Ovarian and Pancreatic v2.2021

2Childers CP, Childers KK, Maggard-Gibbons M, Macinko J. National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer. JCO. 2017 Dec 1; 35:3800-38063.